Clinical Trial

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first). Responding patients with regressing disease are eligible for up to 6 IL-2 cycles. Patients assigned to SBRT arm will receive two doses of SBRT on the Wednesday and Friday before the Monday on which IL-2 starts.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2014-12-02; most recent amendment 2026-07-21.
Status change: Recruiting → Active, Not Recruiting 2022-01-31
Status change: Not Yet Recruiting → Recruiting 2015-06-02
Trial Details
NCT Number NCT02306954
Lead Sponsor Providence Health & Services
Collaborators: Prometheus Laboratories, Cytokine Working Group
Conditions Renal Cell Carcinoma
Enrollment 84 participants
Start Date 2014-12
Primary Completion 2020-09-15 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-23